Vivani, Novo Nordisk to evaluate long-term semaglutide implant
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Anyone who injects Ozempic or Wegovy every week knows it: the ritual quickly becomes a fixed deadline, like paying the rent, complete with reminders on their phone. And then, not to be overlooked, the tedium of constant injections: for some, a real deterrent. Vivani Medical, a biotech company that almost no one outside of Wall Street knows, has been working for years on NPM-139, a semaglutide implant that eliminates that weekly deadline. Novo No…
Vivani, Novo Nordisk to evaluate long-term semaglutide implant
NanoPortal technology held in the hand [Image courtesy of Vivani]Vivani Medical (Nasdaq:VANI) today announced a new agreement with Novo Nordisk to evaluate the NPM-139 long-term semaglutide implant. NPM-139 utilizes the Alameda, California-based company’s NanoPortal platform technology, under development for chronic weight management. Vivani designed NanoPortal technology to steadily deliver medication over extended periods of time. The company …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
